Literature DB >> 29710027

[Two patients with progressive multifocal leukoencephalopathy with immune response against JC virus showing good long-term outcome by combination therapy of mefloquine, mirtazapine, and risperidone].

Yumi Akagawa1, Akihiro Ueno1, Junji Ikeda1, Wataru Ishii2, Yukiko Shishido-Hara3, Yoshiki Sekijima1,4.   

Abstract

Patient 1 was a 59-year-old woman receiving prednisolone for idiopathic hypereosinophilia. Brain MRI of patient 1 disclosed slight gadolinium enhancement at lesions, indicating inflammation. Patient 2 was a 32-year-old woman with systemic lupus erythematosus under immunosuppressive therapy. Brain biopsy of patient 2 showed balanced infiltration of CD8+ and CD4+ T lymphocytes at the sites of lesions. Both subjects were diagnosed as having progressive multifocal leukoencephalopathy (PML) shortly after the onset of neurological symptoms and were treated with a combination of mefloquine, mirtazapine, and risperidone. Both patients remain alive with improved neurological symptoms even after long-term follow-up (24 months in patient 1 and 45 months in patient 2). Although the prognosis of PML is very poor, our findings suggest that pharmacotherapy may be effective for patients with well-controlled immune reactions against the JC virus.

Entities:  

Keywords:  JC virus; mefloquine; mirtazapine; progressive multifocal leukoencephalopathy; risperidone

Mesh:

Substances:

Year:  2018        PMID: 29710027     DOI: 10.5692/clinicalneurol.cn-001166

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  2 in total

Review 1.  Successful treatment of non-HIV progressive multifocal leukoencephalopathy: case report and literature review.

Authors:  Mai Hamaguchi; Keisuke Suzuki; Hiroaki Fujita; Takeo Uzuka; Hadzki Matsuda; Yukiko Shishido-Hara; Satoko Arai; Toshiki Nakamura; Shigeru Kikuchi; Kazuo Nakamichi; Masayuki Saijo; Koichi Hirata
Journal:  J Neurol       Date:  2019-11-14       Impact factor: 6.682

2.  Inflammatory Cerebellar PML with a CD4/CD8 Ratio of 2.9 Showed a Favorable Prognosis in a Patient with Rheumatoid Arthritis.

Authors:  Ryusei Nishigori; Yoko Warabi; Yukiko Shishido-Hara; Kazuo Nakamichi; Yasuhiro Nakata; Takashi Komori; Eiji Isozaki
Journal:  Intern Med       Date:  2019-07-31       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.